Clinical trial

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

NCT04866017

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2021-06-17

PhasePHASE3

Study timeline

Study start (actual)2021-06-17Date precision: day

Registry last updated2024-10-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

TislelizumabDRUG · verified · RxNorm: tislelizumab

DurvalumabDRUG · verified · RxNorm: durvalumab

OciperlimabDRUG

ChemotherapyDRUG

RadiotherapyRADIATION

Sponsors & collaborators

BeiGenelead sponsor

Mapped research locations

GuangzhouGuangdong, China2 TaichungTaiwan2 ChangchunJilin, China2 BarcelonaSpain1 BeijingBeijing Municipality, China1 ShanghaiShanghai Municipality, China1 TaipeiTaiwan1 BeijingChina1 HangzhouZhejiang, China1 NanjingJiangsu, China1 ChangshaHunan, China1 ChengduSichuan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04866017 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.